STOCK TITAN

Mirum Pharmaceuticals - MIRM STOCK NEWS

Welcome to our dedicated page for Mirum Pharmaceuticals news (Ticker: MIRM), a resource for investors and traders seeking the latest updates and insights on Mirum Pharmaceuticals stock.

Mirum Pharmaceuticals (MIRM) delivers innovative therapies for rare liver diseases through targeted IBAT inhibitor development. This page provides centralized access to official announcements, clinical trial updates, and strategic developments from the biopharmaceutical innovator.

Investors and healthcare professionals will find timely updates on regulatory milestones, partnership agreements, and pipeline advancements. Our curated feed includes verified press releases about Maralixibat approvals, Volixibat trial progress, and corporate initiatives addressing conditions like progressive familial intrahepatic cholestasis.

Key updates cover FDA communications, research collaborations, and commercialization strategies for orphan drug therapies. All content is sourced directly from Mirum’s disclosures to ensure accuracy and compliance with financial reporting standards.

Bookmark this page for streamlined access to Mirum’s latest advancements in minimally absorbed liver disease treatments. Check regularly for critical updates impacting clinical development timelines and therapeutic availability.

Rhea-AI Summary
Mirum Pharmaceuticals to participate in fireside chat at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.7%
Tags
conferences
-
Rhea-AI Summary
Mirum Pharmaceuticals appoints Eric Bjerkholt as CFO, bringing extensive business leadership experience from the biopharmaceutical industry. Bjerkholt's appointment is seen as important for Mirum's growth and global scale. He is granted 110,000 shares of common stock and 55,000 restricted stock units. Bjerkholt's appointment and stock grants indicate positive prospects for Mirum's future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
management
-
Rhea-AI Summary
Mirum Pharmaceuticals grants inducement awards to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
none
Rhea-AI Summary
Mirum Pharmaceuticals, Inc. to participate in upcoming investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.22%
Tags
conferences
-
Rhea-AI Summary
Mirum acquires Travere's rights and assets for Cholbam® and Chenodal®, paying $210 million upfront with potential for $235 million in milestone payments. Expands Mirum's rare liver disease portfolio and strengthens Travere's financial foundation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.46%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
none
Rhea-AI Summary
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) reported $37.5 million total revenue for Q2 2023, including $32.5 million net product sales for LIVMARLI. The company is acquiring CHENODAL® and CHOLBAM®, and expects four late-stage clinical trial data readouts later this year. The PR highlights the financial results, business updates, and future catalysts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.31%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
none
Rhea-AI Summary
Mirum Pharmaceuticals and Travere Therapeutics have entered into a definitive agreement for the sale of Travere's bile acid product portfolio. Mirum will acquire Travere's rights to Cholbam® and Chenodal® for $445 million, with $210 million upfront and up to $235 million in potential sales-based milestones. Mirum has secured $210 million in funding to finance the upfront payment. The transaction is expected to close in Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.39%
Tags
Mirum Pharmaceuticals

Nasdaq:MIRM

MIRM Rankings

MIRM Stock Data

1.93B
41.61M
2.16%
113.24%
13.52%
Biotechnology
Pharmaceutical Preparations
Link
United States
FOSTER CITY